Spermosens AB (publ) INTERIM REPORT APRIL - JUNE 2026

In the second quarter of 2026, we saw recruitment into its Generation 3 clinical validation study exceed expectations, broadened partnership discussions across markets, and secured working capital

1 APRIL - 30 JUNE 2026

SIGNIFICANT EVENTS DURING THE INTERIM PERIOD 

8 April, 2026 Spermosens completes development of JUNO-Checked Generation 3 and initiates clinical                             validation study

29 April, 2026 Spermosens reports JUNO-Checked Generation 3 clinical validation study on track

7 May, 2026 Spermosens AB (publ) INTERIM REPORT JANUARY - MARCH 2026

7 May, 2026 Spermosens secures SEK 4.85 million capital facility to support development and                                                                             commercialization

18 May, 2026 NOTICE OF ANNUAL GENERAL MEETING 2026 IN SPERMOSENS AB (publ)

28 May, 2026 Spermosens publishes annual report for the financial year 2025

18 June, 2026 Bulletin from Annual General Meeting in Spermosens AB (publ)

SIGNIFICANT EVENTS AFTER THE END OF THE INTERIM PERIOD

1 July, 2026 Spermosens provides an update on the Generation 3 clinical study

21 July, 2026 Spermosens calls SEK 4.85 million under previously announced Capital Facility

6 August, 2026 Spermosens raises approx. SEK 4.85m in directed issue and calls EGM

6 August, 2026 Notice of Extraordinary General Meeting in Spermosens AB (publ)

FINANCIAL INFORMATION

 CEO STATEMENT

The last quarter has seen strong recruitment into our clinical validation of JUNO-Checked Generation 3, and the pace continues. The goal is to show that this new generation of sensors can measure the binding of sperm cells to the egg accurately and efficiently, giving doctors and patients better answers.

Alongside the study, we deepened and expanded our partner discussions. We continue to attract relevant commercial partners, ones with the capacity to bring JUNO-Checked to market, as well as clinical partners for independent validation of our system and partners for manufacturing and supply.

This quarter we also strengthened the company's finances through a flexible and cost-effective capital facility approved by shareholders at the Annual General Meeting in June. It secures the company's runway, backed by existing shareholders who have shown long-term commitment to the company.

As communicated earlier, we spent the early part of the year developing a new generation of sensors with improved reproducibility and usability. The clinical study with this generation started in April, according to plan, and it proved easy to use with high reproducibility. We spent time adjusting the sample preparation to achieve optimal capacitation of the sperm cells before testing. Recruitment has exceeded our expectations, with 44 patients recruited before the summer break at the Reproductive Medicine Centre (RMC) in Malmö. Recruitment will resume in mid-August, and we still plan to complete the study by the end of the year.

We stayed active in our partner discussions, looking at how our technology fits the business models of potential partners and the right go-to-market strategy for each. That work has also expanded the field of potential partners. At the ESHRE Annual Congress in London, one of the most important global congresses for reproductive medicine, we presented the clinical results from our second-generation JUNO-Checked sensor and received strong interest from companies and scientists. We made new contacts in Japan too, a market we see as highly relevant for JUNO-Checked. We are in ongoing discussions with potential partners for independent clinical validation in another territory. A second site would provide more data, demonstrate the system's value in a different clinical setting, and build broader trust and visibility for JUNO-Checked. We are also talking to potential partners for manufacturing and supply, something we need in place before we can bring JUNO-Checked to market at scale.

Over the past two years we trimmed the organization and reduced our fixed cost base, which lets us operate with a reduced need for capital. We had stretched our liquidity into September this year, but to achieve our goals, completing the clinical study and finding commercial partners, we needed to secure additional capital.

In collaboration with existing shareholders, we established a flexible and cost-effective capital facility of SEK 4.85 million before issue costs. We consider this the best solution from both a cost and a time perspective. It secures runway throughout the year, and the TO6 warrants coming up in November may bring additional capital. This capital allows us to complete the study and advance our partner discussions, with the ambition of moving into license agreements.

We are pleased with the progress and we stay on plan, focused on reaching our milestones. Each one gets us closer to giving doctors and patients useful answers, and that's what keeps us motivated. I want to thank our investors for their trust and support. We are working to make this a success for all our shareholders.

Tore Duvold, CEO of Spermosens